CDMO secures a $98M+ NIH contract for production of pediatric HIV-prevention products
Advanced BioScience Laboratories, a CDMO specializing in biotherapies, viral vector-based vaccines and oncolytics, has received a development and manufacturing contract from the US government.
ABL has been awarded a seven-year contract with a potential value of $98.9 million to provide resources to Pediatrics and HIV Prevention Science by the National Institutes of Health’s Division of AIDS. Specifically, ABL will provide the Division of AIDS with preclinical work, animal models and analytical services manufacturing to advance non-vaccine biomedical HIV products such as intravaginal rings and long-acting injectables that aim to prevent STIs, HIV or pregnancy.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters